logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

USD bond abnormal movement | Fujian Zhanglong Group ZHANLO 5.1 04/24/28 price increased 1.593% to 101.750.

date
05/11/2025
On November 5th, ZHANLO 5.1 04/24/28 issued by Fujian Zhanglong Group is currently priced at 101.750, up by +1.593% with a yield of 4.343%.
Latest
2 m ago
Sinopharm Biological (09688): Updates on the Phase 1b/3 clinical study FORTITUDE-102 of Amgen's Bevacizumab Biosimilar
2 m ago
"UPS cargo plane crash has resulted in 3 deaths and 11 injuries."
2 m ago
Democratic candidate Spanberger wins Virginia governor election.
3 m ago
According to Every AI Express, Pacific Securities issued a research report on November 5th giving a "buy" rating to Kangchen Pharmaceutical (603590.SH). The main reasons for the rating include: 1) Marketing transformation and indication expansion improve the market space for thrombin; 2) The innovative drug pipeline is progressing smoothly, actively laying out more pipelines. (Daily Economic News)
4 m ago
AI Express of Every Economy, Pacific Securities issued a research report on November 5th, giving a "buy" rating to Yingke Medical (300677.SZ). The rating reasons mainly include: 1) The leading glove production capacity and cost advantages, with overseas production in sight and ample room for future expansion; 2) The logic of glove price increases is expected to be realized, with sufficient upside potential; 3) Gross margin and cost ratio have slightly increased. (Daily Economic News)
See all latestmore
logo
Contact US
qr
+852 - 60190728
[email protected]
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.